- Biologically Active Peptides
- Enzyme Inhibitors
- Polypeptides
- Oligopeptides
- Others
Peptide API Market size was valued at USD 1.5 billion in 2023 and is poised to grow at a CAGR of 12.2% from 2024 - 2030. The peptide API (Active Pharmaceutical Ingredient) market has been experiencing growth in recent years due to the advancements in peptide synthesis, increasing demand for therapeutic peptides, and their effectiveness in treating various diseases. The market has been growing, driven by the rising prevalence of chronic diseases such as diabetes, cancer, and metabolic disorders. Peptide APIs offer effective treatments for such conditions. Complexities in manufacturing, stringent regulatory requirements, limited drug delivery methods affecting efficacy, and high development costs are expected to restrain the market growth.
Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment hot spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global peptide API products. The three most common therapeutic areas where peptide APIs are used are oncology, diabetes, and obesity. Peptides are also highly demanded as antibiotics and vaccines for treating cardiovascular, renal, and other diseases. Currently, injection is used to administer more than 80% of authorized peptide medicines. Oral and other forms of delivery are becoming more popular.
Global Peptide Api Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.2%
Largest Market
North America
Fastest Growing Market
Europe
Peptide API Market Dynamics
owing to increase in scientific advancements and rising number of pharmaceutical and biopharmaceutical companies across the globe are expected to propel the growth of the market. Additionally, launch of novel technologies and strategic collaborations between the market players are expected to enhance the sales of the market. However manufacturing peptide API is a complex process that involves sophisticated technology and expert oversight are expected to hamper the growth of the market.
North-America Got Significant Share
Peptide API Market Regional Analysis
North America is a leader in the peptide API market, primarily due to established pharmaceutical industries, robust research infrastructure, and a high prevalence of chronic diseases. The region has the presence of major pharmaceutical companies investing heavily in peptide-based therapeutics. These companies drive innovation and R&D in peptide API development. Europe is the second leading region after North America in the peptide API market. Countries like Germany, Switzerland, and the UK are key contributors due to their strong biotech and pharmaceutical sectors. The Asia-Pacific region is experiencing significant growth in the peptide API market due to increasing investments in healthcare infrastructure and pharmaceutical manufacturing capabilities.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Peptide Api Market Segmentation
By Category
By Therapeutic Area
- Cancer
- Cardiovascular
- Respiratory
- Nervous Systems
- Gastrointestinal
- Others
By End User
- Biopharmaceutical Companies
- Pharmaceutical Companies
- Research Institutes & Universities
- Others
By Geography
- North America
- Latin America
- Europe
- Middle East and Africa
- Asia Pacific
Frequently Asked Questions
The peptide api market size was valued at USD 187 million in 2023
The peptide api market key players are: CordenPharma Hemmo Pharmaceuticals Pvt Ltd. Auspep (Australia) BACHEM BAM Biotech Company CS Bio (California) Almac Group Tapi Teva Novetide Lyotex Sciences Aspen Oss Peptide Institute Inc.
The peptide api market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Peptide API Market Introduction |
| 2.1. Global Peptide API Market Taxonomy |
| 2.2. Global Peptide API Market Definitions |
| 2.2.1. Category |
| 2.2.2. Therapeutic Area |
| 2.2.3. End User |
| 2.2.4. Region |
| 3. Global Peptide API Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Peptide API Market Dynamic Factors - Impact Analysis |
| 3.6. Impact of COVID 19 on The Market |
| 3.7. Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
| 3.8. Mapping Market Playes Activities |
| 3.9. Recent Key Developments |
| 3.10. Financial Status of the Market Players |
| 3.11. Recent Acquisitions, Collaborations, and Mergers |
| 4. Global Peptide API Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Peptide API Market Analysis, By Category, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 5.1. Biologically Active Peptides |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Enzyme Inhibitors |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Polypeptides |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Oligopeptides |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Peptide API Market Analysis, By Therapeutic Area, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 6.1. Cancer |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Cardiovascular |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Respiratory |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Nervous Systems |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Gastrointestinal |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Peptide API Market Analysis, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 7.1. Biopharmaceutical Companies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Pharmaceutical Companies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Research Institutes & Universities |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Peptide API Market Analysis, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. The Middle East and Africa |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Peptide API Market - Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Region, 2024 - 2030 |
| 9. North America Peptide API Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 9.1. Category Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Biologically Active Peptides |
| 9.1.2. Enzyme Inhibitors |
| 9.1.3. Polypeptides |
| 9.1.4. Oligopeptides |
| 9.1.5. Others |
| 9.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Cancer |
| 9.2.2. Cardiovascular |
| 9.2.3. Respiratory |
| 9.2.4. Nervous Systems |
| 9.2.5. Gastrointestinal |
| 9.2.6. Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Biopharmaceutical Companies |
| 9.3.2. Pharmaceutical Companies |
| 9.3.3. Research Institutes & Universities |
| 9.3.4. Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. The U.S. |
| 9.4.2. Canada |
| 9.5. North America Peptide API Market - Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2024 - 2030 |
| 9.6. North America Peptide API Market Dynamics Trends |
| 10. Europe Peptide API Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 10.1. Category Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Biologically Active Peptides |
| 10.1.2. Enzyme Inhibitors |
| 10.1.3. Polypeptides |
| 10.1.4. Oligopeptides |
| 10.1.5. Others |
| 10.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Cancer |
| 10.2.2. Cardiovascular |
| 10.2.3. Respiratory |
| 10.2.4. Nervous Systems |
| 10.2.5. Gastrointestinal |
| 10.2.6. Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Biopharmaceutical Companies |
| 10.3.2. Pharmaceutical Companies |
| 10.3.3. Research Institutes & Universities |
| 10.3.4. Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. The UK |
| 10.4.3. France |
| 10.4.4. Italy |
| 10.4.5. Spain |
| 10.4.6. Rest of Europe |
| 10.5. Europe Peptide API Market - Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2024 - 2030 |
| 10.6. Europe Peptide API Market Dynamics Trends |
| 11. Asia-Pacific Peptide API Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 11.1. Category Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Biologically Active Peptides |
| 11.1.2. Enzyme Inhibitors |
| 11.1.3. Polypeptides |
| 11.1.4. Oligopeptides |
| 11.1.5. Others |
| 11.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Cancer |
| 11.2.2. Cardiovascular |
| 11.2.3. Respiratory |
| 11.2.4. Nervous Systems |
| 11.2.5. Gastrointestinal |
| 11.2.6. Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Biopharmaceutical Companies |
| 11.3.2. Pharmaceutical Companies |
| 11.3.3. Research Institutes & Universities |
| 11.3.4. Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Peptide API Market - Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2024 - 2030 |
| 11.6. Asia-Pacific Peptide API Market Dynamics Trends |
| 12. Latin America Peptide API Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 12.1. Category Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Biologically Active Peptides |
| 12.1.2. Enzyme Inhibitors |
| 12.1.3. Polypeptides |
| 12.1.4. Oligopeptides |
| 12.1.5. Others |
| 12.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Cancer |
| 12.2.2. Cardiovascular |
| 12.2.3. Respiratory |
| 12.2.4. Nervous Systems |
| 12.2.5. Gastrointestinal |
| 12.2.6. Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Biopharmaceutical Companies |
| 12.3.2. Pharmaceutical Companies |
| 12.3.3. Research Institutes & Universities |
| 12.3.4. Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Argentina |
| 12.4.3. Mexico |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Peptide API Market - Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2024 - 2030 |
| 12.6. Latin America Peptide API Market Dynamics Trends |
| 13. The Middle East and Africa Peptide API Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
| 13.1. Category Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Biologically Active Peptides |
| 13.1.2. Enzyme Inhibitors |
| 13.1.3. Polypeptides |
| 13.1.4. Oligopeptides |
| 13.1.5. Others |
| 13.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Cancer |
| 13.2.2. Cardiovascular |
| 13.2.3. Respiratory |
| 13.2.4. Nervous Systems |
| 13.2.5. Gastrointestinal |
| 13.2.6. Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Biopharmaceutical Companies |
| 13.3.2. Pharmaceutical Companies |
| 13.3.3. Research Institutes & Universities |
| 13.3.4. Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1. GCC Countries |
| 13.4.2. South Africa |
| 13.4.3. Israel |
| 13.4.4. Rest of MEA |
| 13.5. MEA Peptide API Market - Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2024 - 2030 |
| 13.6. MEA Peptide API Market Dynamics Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, CategoryOfferings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. CordenPharma |
| 14.2.2. Hemmo Pharmaceuticals Pvt Ltd. |
| 14.2.3. Auspep (Australia) |
| 14.2.4. BACHEM |
| 14.2.5. BAM Biotech Company |
| 14.2.6. CS Bio (California) |
| 14.2.7. Almac Group |
| 14.2.8. Tapi Teva |
| 14.2.9. Novetide |
| 14.2.10. Lyotex Sciences |
| 14.2.11. Aspen Oss |
| 14.2.12. Peptide Institute I |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- CordenPharma
- Hemmo Pharmaceuticals Pvt Ltd.
- Auspep
- BACHEM
- BAM Biotech Company
- CS Bio
- Almac Group
- Tapi Teva
- Novetide
- Lyotex Sciences
- Aspen Oss
- Peptide Institute Inc.